Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have been given a consensus recommendation of “Moderate Buy” by the eight research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $55.50.

A number of equities research analysts recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, April 10th. Lucid Cap Mkts raised Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Wall Street Zen lowered Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. Finally, BTIG Research restated a “buy” rating and set a $15.00 target price on shares of Tvardi Therapeutics in a report on Wednesday, April 1st.

Tvardi Therapeutics Price Performance

Shares of Tvardi Therapeutics stock opened at $4.00 on Friday. Tvardi Therapeutics has a 1 year low of $2.75 and a 1 year high of $43.65. The business has a 50-day moving average of $3.44 and a two-hundred day moving average of $3.89. The company has a market capitalization of $37.52 million, a P/E ratio of -1.29 and a beta of 0.30.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.08). On average, equities analysts anticipate that Tvardi Therapeutics will post -2.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in Tvardi Therapeutics in the fourth quarter valued at $55,000. Quadrature Capital Ltd bought a new position in Tvardi Therapeutics in the fourth quarter valued at $90,000. Russell Investments Group Ltd. grew its position in Tvardi Therapeutics by 1,351.5% in the fourth quarter. Russell Investments Group Ltd. now owns 15,966 shares of the company’s stock valued at $69,000 after purchasing an additional 14,866 shares in the last quarter. Squarepoint Ops LLC grew its stake in Tvardi Therapeutics by 534.3% in the fourth quarter. Squarepoint Ops LLC now owns 51,783 shares of the company’s stock valued at $223,000 after purchasing an additional 43,619 shares in the last quarter. Finally, Arax Advisory Partners grew its stake in Tvardi Therapeutics by 277.2% in the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after purchasing an additional 6,173 shares in the last quarter. Institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.